Trial
NCT00496366
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Rutgers, The State University of New Jersey
Collaborators
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey
Condition
Breast Cancer
Intervention
Capecitabine
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-21